Graduate Accountant – Specialist Taxation – Part Time
Swanson Reed is a leading firm in the area of R&D tax credits and innovation incentives. We employ Engineers, Scientists and Accountants to service a diverse range of clients from technology start-ups to billion dollar Government Owned Corporations in the commercial aspects of research, development, management and technology transfer. Swanson Reed seeks to recruit a Graduate Accountant to join their energetic team.
This is an excellent opportunity to utilise your accounting expertise in the finance sector through assisting to shape small to large mining, manufacturing and construction companies with their commercially sensitive innovation agendas and corporate planning.
You will help structure R&D activities so a company may attain the maximum possible Government entitlements
You will be accountable for the identification, analysis, structuring, costing, modelling and submission of highly confidential R&D projects
You will assist with the development of R&D plans and
You will assist with financial modelling / costings
You will work with a vast array of company executives to solve their complex commercial problems
You will receive on the job training (option ofMBA,CA, CFA or CPA will be provided) and guided until you are fully competent
You will possess tertiary qualifications in Finance, Accounting or Taxation
1+ years Accounting experience in the manufacturing, construction, general engineering sectors or professional environment will be viewed favourably
An individual with an inquisitive and technical mind with a wish to be involved in the strategic branding of our business will excel in this role.
The National Institute of Health (NIH) is investing $248.7 million in new technologies to address challenges associated with COVID-19 testing. NIH’s Rapid Acceleration of Diagnostics (RADx) initiative has awarded contracts to seven biomedical diagnostic companies to support a range of new lab-based and point-of-care tests that could significantly increase the number, [...]
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers and 60% of these have wild-type epidermal growth factor receptor (EGFR) mutations. [...]